1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMetastatic Brain Tumor Collaborative Research Grants is sponsored by Metastatic Brain Tumor Collaborative. Supports innovative projects aimed at improving diagnosis and treatment of CNS metastases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Metastatic Brain Tumor Collaborative Announces First-Ever Collaborative Grant Opportunity Focused on CNS Metastasis - American Brain Tumor Association Metastatic Brain Tumor Collaborative Announces First-Ever Collaborative Grant Opportunity Focused on CNS Metastasis Grants Support Innovative, High-Risk Research Aimed at Improving Diagnosis and Treatment of CNS Metastases CHICAGO, October 15, 2025 — The Metastatic Brain Tumor Collaborative (MBTC) , created by the American Brain Tumor Association (ABTA) announced $100,000 in research grants to support innovative projects aimed at improving the diagnosis, treatment, and understanding of central nervous system (CNS) metastases.
This represents the first-ever collaborative grant opportunity dedicated to CNS metastasis, made possible through the collective effort of ten leading nonprofit cancer organizations. CNS metastases are the most common type of brain tumor in adults, occurring when cancers such as breast, lung, melanoma, colorectal, and kidney spread to the brain or spinal cord.
Despite affecting more than 200,000 people in the U.S. each year, this patient population remains vastly underrepresented in research and clinical care. Announcing this milestone underscores the urgency of advancing research that benefits patients across cancer types.
The MBTC’s CNS Metastasis Research Grants provide $50,000 for one-year seed funding to high-risk, high-impact projects with the potential to transform how metastatic brain tumors are detected and managed. Each funded project must address CNS metastases arising from at least two distinct primary cancer types, with potential benefit to adult and/or pediatric populations.
The selected teams receiving MBTC grant funding include: Investigator: Sherise Ferguson, MD Institution: The University of Texas MD Anderson Cancer Center Project Title: Evaluating the therapeutic efficacy of NK cell immunotherapy for CNS metastasis Investigator: Alireza Mansouri, MD Institution: The Pennsylvania State University College of Medicine Project Title: Cerebrospinal Fluid Proteomic Signatures of Leptomeningeal Disease The selected projects reflect a wide range of research focus areas, including: immunotherapy, tumor biology, improving diagnosis, and biomarkers of treatment response.
By providing these grants, the MBTC aims to support these researchers to generate foundational data that will support future clinical translation and larger-scale funding. “Metastatic brain tumors are devastating, and yet, historically overlooked,” said Nicole Willmarth, PhD, Chief Mission Officer of the American Brain Tumor Association.
“This groundbreaking collaborative grant program, led by the ABTA and made possible through the collective effort of cancer organizations across multiple disease areas, is a turning point for patients with CNS metastases. Together, we are fueling bold, innovative research that has the potential to change the trajectory of care for this underserved population.
” About the Metastatic Brain Tumor Collaborative The Metastatic Brain Tumor Collaborative is a coalition of nonprofit organizations dedicated to improving the lives of patients with brain metastases through research, education, and support. The MBTC fosters cross-disease collaboration and drives investment into research specifically focused on CNS metastases, a historically underfunded and clinically complex area.
Organizations supporting this CNS Metastasis Research Grant initiative include: American Brain Tumor Association Kidney Cancer Association Melanoma Research Foundation Metastatic Breast Cancer Alliance Other MBTC partners include: Living Beyond Breast Cancer Society for Neuro-Oncology For more information, visit abta. org/metastatic-brain-tumor-collaborative . Tagged Metastatic Brain Tumor Collaborative
According to the current listing, eligibility includes: Researchers from multiple institutions focusing on CNS metastases. Confirm the full requirements in the official notice before applying.
The current listing shows $100,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Metastatic Brain Tumor Collaborative Research Grants is funded by Metastatic Brain Tumor Collaborative. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Notice 20260916-RZ funds teams of humanities scholars at up to $250,000 over three years, with a separate $50,000 planning track for international collaborations. The 2026 competition accepts only projects on the history and culture of the United States or Western civilization. At roughly 134 applications for 14 to 15 awards, the eligibility screen matters more than the writing.
Read articleHumanity AI — a collaborative of ten funders including Ford, MacArthur, Mellon, and Mozilla — announced more than $18M to align AI with democratic values. $8M went to 12 invited grantees at $500K each; a $10M open call launches summer 2026. Here is who got funded, what the money signals, and how mission-aligned nonprofits should position for the open round.
Read articleARPA-H's HEARING program (ARPA-H-SOL-26-154) — Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy — held its Proposers' Day on June 8, 2026 and set Solution Summary deadlines for June 29 with Full Proposals due August 14. Single prime awardee, multiple Other Transaction Agreements, three integrated technical areas spanning intracortical recording and stimulation devices, wearable dynamic sound modulators, and AI-based auditory read/write algorithms. The first phase runs 18 months; the full effort runs 4.5 years through first-in-human clinical studies. For neurotech teams that have spent a decade in cochlear-implant or visual-prosthesis space, this is the moment the federal government bet on auditory cortex over the cochlea.
Read article